BENGALURU (Reuters) – Sun Pharmaceutical Industries Ltd said on Thursday the U.S. Food and Drug Administration (FDA) had listed the Indian drugmaker’s facility in the western state of Gujarat under an import alert.
The import alert means all future shipments of products made at Halol can be refused admission to the U.S. market until the facility becomes compliant with the FDA’s Current Good Manufacturing Practice standards, the company said.
(Reporting by Navamya Ganesh Acharya in Bengaluru; Editing by Subhranshu Sahu)
Disclaimer: This report is auto generated from the Reuters news service. ThePrint holds no responsibilty for its content.